June 2005- Volume 1, Issue 4

June 2005

In this Issue

Automation & Instrumentation

Upstate, CXR Biosciences begin development of early-stage in vitro tox screening platform

Upstate, CXR Biosciences begin development of early-stage in vitro tox screening platform

Late last month, Upstate Group, a division of Serologicals Corp., and CXR Biosciences announced the two companies would work together to create an early-stage toxicology screening platform the companies believe will allow for more effective screening of drug candidate compounds.

Roche, 454 Life Sciences team up: Roche signs worldwide agreement to market 454’s Genome Sequencing System

Roche, 454 Life Sciences team up: Roche signs worldwide agreement to market 454’s Genome Sequencing System

Roche Diagnostics announced in early May that it had entered into an exclusive, five-year, world-wide agreement for the development, promotion, sale and distribution of 454 Life Science’s nanotechnology-based Genome Sequencing Systems, including proprietary kits and reagents. Under the terms of the agreement, 454, a division of CuraGen Corp., will receive up to $62 million in license fees, milestone payments related to instrument releases, minimum royalties and research funding.

Pumping up peptide production

Pumping up peptide production

AA Peptides, LLC, doing business as AAPPTec (Advanced Automated Peptide Protein Technologies), announced in May it purchased the instrument division of Advanced ChemTech (ACT). Hossain Saneii, AAPPTec’s chief operating officer, said AAPPTec will manufacture and sell parts and instruments, and provide continued customer service and technical support for ACT peptide manufacturing equipment. The ACT technology is “well-known in the peptide field,” says Saneii, “very established” and capable of all scales of peptide production. AAPPTec also obtained patent rights to the instruments.

BD Diagnostics goes proteomic: Acquires German electrophoresis company FFE Weber GmbH

BD Diagnostics goes proteomic: Acquires German electrophoresis company FFE Weber GmbH

BD Diagnostics announced in early May that it had acquired German proteomics and instrumentation provider FFE Weber GmbH. The purchase gives BD a foothold in the growing proteomics research market as well as a technology the company feels could become an important diagnostic tool in the coming years.

Nanostream intros Veloce add-on

Nanostream intros Veloce add-on

Nanostream Inc. earlier this month rolled out a fraction collector add-on to it Veloce micro parallel liquid chromatography system. The fraction collector was developed in response to customers who were looking to take advantage of the Veloce system as a sample preparation device for mass spec applications.

Magellan says: automate this

Magellan says: automate this

After the acquisition of TekCel, Magellan Biosciences indirectly continues to expand its automation instrument empire as TekCel announces its acquisition of ultra-low-temperature sample-management specialist Biophile, Inc., based in Charlottesville, Virginia. Biophile's systems are used for temperature-sensitive work involving DNA, tissue, and tumor storage, and complement the automation systems already in play at TekCel and Magellan Bioscience.

Informatics

Entelos, ADA team up for in silico modeling

Entelos, ADA team up for in silico modeling

At the 65th Annual American Diabetes Association Meeting, Entelos presented data from their collaboration with the ADA in two poster sessions. One poster described a comprehensive analysis on the time-dependent effects of treatment in a mouse model for human type 1 diabetes. The other presentation described the company's Type 1 Diabetes PhysioLab modeling platform, which offers large-scale mathematical simulations of disease pathology and therapeutic intervention in the model mice.

Public/private partnership: OSU Medical Center and BioImagene to combine efforts

Public/private partnership: OSU Medical Center and BioImagene to combine efforts

The Ohio State University College of Medicine and BioImagene, a bio-image analysis products company based here, have signed an agreement to engage in numerous collaborative activities, including joint research proposals at the state and national levels, joint projects with profit potential, and other mutually beneficial activities.

Technology license: WRI, InforSense to develop next-generation system for translational medicine

Technology license: WRI, InforSense to develop next-generation system for translational medicine

Integrative analytical technology specialist InforSense announced in May the licensing of its workflow-based informatics platforms by the Windber Research Institute (WRI), a biomedical research center looking for cures to genetic and metabolic diseases. The two organizations will work together to develop a production-quality, generic informatics framework for translational medicine to be used by WRI and its clinical collaborators.

E-learning duo: GeneEd, Zenosis provide end-to-end educational service

E-learning duo: GeneEd, Zenosis provide end-to-end educational service

GeneEd and Zenosis, two companies focused on delivering e-learning curricula for the pharmaceutical industry, announced in early May they will work together to provide a single, end-to-end educational service for life science companies. The combination of services will provide courses in everything from basic life science skills all the way to clearing regulatory hurdles for drug approval.

Insightful wins federal awards

Insightful wins federal awards

Insightful Corp. announced in mid-May that it received two awards for bioinformatics work under the U.S. government’s Small Business Innovation Research (SBIR) program. A Phase II contract with the U.S. Air Force (USAF) and a Phase I grant from the National Institutes of Health (NIH) are worth a total of approximately $850,000. Both projects involve Insightful’s InFact software, which performs natural language-based analysis and search functions on large quantities of text.

Research & Development

Smaller is better: Bentley Pharmaceuticals, UNH team up on Nanocaplets

Smaller is better: Bentley Pharmaceuticals, UNH team up on Nanocaplets

The results of a four-year sponsored research program with the University of New Hampshire (UNH) Nanostructured Polymers Research Center came to fruition in early May when Bentley Pharmaceuticals announced its new Nanocaplet technology.

GSK to acquire Corixa: Purchase includes adjuvant supply and vaccine pipeline

GSK to acquire Corixa: Purchase includes adjuvant supply and vaccine pipeline

Corixa announced that the waiting period imposed by Hart-Scott-Rodino Act for their proposed sale to GSK Biologicals has expired. Corixa stockholders will attend a special meeting on July 12, 2005 at Corixa's corporate headquarters to consider the adoption of the agreement. The two companies expect to complete the agreement quickly thereafter and when all conditions to the transaction are satisfied or waived.

Ardais completes strategic transition

Ardais completes strategic transition

The late March announcement that Cambridge, U.K.-based Cytomix would acquire Ardais Corp.’s biorepository of more than 130,000 biospecimens was much more than a simple transaction for Ardais. It marked the completion of a year-long strategic remaking of Ardais that moved the company from a provider of biospecimens for the research community, to a consultant whose services help research centers manager their internal tissue collection and biospecimen management systems.

EndoBiologics, VaxGen target meningitis B

EndoBiologics, VaxGen target meningitis B

Vaccine specialist VaxGen recently announced a collaborative effort with privately held biotechnology company EndoBiologics International to pursue research into a vaccine that targets meningitis B, a bacterial disease that targets children and can lead to mental retardation, loss of limbs, and even death. According to Atlanta’s Centers for Disease Control and Prevention, meningitis attacks approximately 1 in every 100,000 people worldwide, but regional epidemics can kill tens of thousands of people.

New stem cell source: BioE provides cloned stem cell lines from umbilical cord blood

New stem cell source: BioE provides cloned stem cell lines from umbilical cord blood

Biotechnology company BioE announced in May that it would make commercially available stem cell lines cloned from human umbilical cord blood rather than obtained from human embryos. The company is reportedly the first firm to come to market with such lines, which it refers to as Multi-Lineage Progenitor Cells (MLPCs).

Genomics & Proteomics

Neurologix and Keio University in gene deal

Neurologix and Keio University in gene deal

Neurologix, Inc. has licensed the humanin gene from Keio University in Tokyo, an agreement providing Neuro-logix exclusive worldwide rights (excluding Japan) to develop and commercialize therapeutics to treat brain and other central nervous system (CNS) disorders (excluding amyotrophic lateral sclerosis) using the technology. The humanin gene will be used in combination with Neurologix’s proprietary gene transfer technology and is expected to be the company’s lead compound for a novel and promising approach to Alzheimer’s disease.

CombiMatrix forms subsidiary: CombiMatrix Molecular Diagnostics to focus on personalized medicine

CombiMatrix forms subsidiary: CombiMatrix Molecular Diagnostics to focus on personalized medicine

For many in the pharmaceutical and medical industries, personalized medicine has become the latest holy grail, and CombiMatrix Corp. believes it has the right DNA microarray capabilities to be a leader in making personalized medicine a reality. As such, the company recently formed a wholly owned subsidiary called CombiMatrix Molecular Diagnostics (CMD), which will be led by two former executives of Irvine, Calif.-based US Labs.

Invitrogen to acquire Caltag

Invitrogen to acquire Caltag

Invitrogen Corp. announced in mid-May it had signed a definitive agreement to acquire privately held immunological assay manufacturer Caltag Laboratories in a cash transaction totaling $20 million.

Proteomic Pact: PerkinElmer chooses Nonlinear Dynamics as its exclusive proteomics informatics provider

Proteomic Pact: PerkinElmer chooses Nonlinear Dynamics as its exclusive proteomics informatics provider

Further cementing a business relationship forged in the late 1990s, PerkinElmer and Nonlinear Dynamics announced in late April that PE will distribute Nonlinear’s complete range of 1D, 2D and array software and that it named Nonlinear as the exclusive provider of informatics software for its proteomics line.

Health Discovery gets SVM patents

Health Discovery gets SVM patents

Health Discovery Corp. may not hold all the cards when it comes to marketing and development of support vector machine (SVM) technology—the likely successor to neural networks. But it certainly has come very close with the recent completion of its acquisition of an extensive SVM patent portfolio previously owned by BioWulf Technologies and BioWulf Genomics.

Global News

FDA Commissioner Crawford to deliver DDT keynote

FDA Commissioner Crawford to deliver DDT keynote

Newly designated FDA Commissioner Lester Crawford will deliver a keynote address at the 10th Annual Drug Discovery Technology & Development World Congress, scheduled for August 8-11 at the Boston Convention & Exhibition Center here. Dr. Crawford’s speech, “New Regulatory Directions for the 21st Century,” will explore the theme of the conference “Optimizing the Discovery and Development Interface to Improve Productivity.” His remarks will focus on new regulatory and scientific steps to make the introduction of novel drugs more predictable and less time-consuming. He will also elaborate on the FDA’s reforms designed to facilitate the modernization of drug manufacturing and to strengthen the safety of marketed medicines.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022